We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Japan’s PMDA Clarifies Requirements for Companion Diagnostic PMAs
Japan’s PMDA Clarifies Requirements for Companion Diagnostic PMAs
Companies filing premarket approval applications for companion diagnostics may explain the clinical significance and clinical cut-off of their products using a summary of the clinical results for the corresponding drug product, recent technical guidance from Japan’s Pharmaceuticals and Medical Devices Agency says.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor